Significant Ownership of Squadron Capital Management LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Squadron Capital Management LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Matthew Sesterhenn - Partner
- Manager location
- Westmont, IL
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Squadron Capital Management LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Squadron Capital Management LLC
Significant Ownership of Squadron Capital Management LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| RLMD | RELMADA THERAPEUTICS, INC. | Common Stock ($.001 par value) | 9.9% | $31,283,007 | +$17,330,352 | 7,395,510 | +124% | Squadron Master Fund LP | 31 Dec 2025 |
| NXTC | NextCure, Inc. | Common Stock, $0.001 par value per share | 9.9% | $3,521,940 | +$1,263,485 | 271,127 | +56% | Squadron Master Fund LP | 31 Dec 2025 |
| KTTA | Pasithea Therapeutics Corp. | Common Stock, par value $0.0001 per share | 9.9% | $2,050,179 | +$67,601 | 2,329,749 | +3.4% | Squadron Master Fund LP | 31 Dec 2025 |
| APRE | Aprea Therapeutics, Inc. | Common Stock | 9.9% | 1,271,081 | Squadron Master Fund LP | 30 Mar 2026 | |||
| INM | InMed Pharmaceuticals Inc. | Common Shares, no par value | 9.8% | $208,000 | 325,000 | Squadron Master Fund LP | 19 May 2026 | ||
| SCYX | SCYNEXIS INC | Common Stock, par value $0.001 per share | 9.6% | $6,771,739 | 7,608,695 | Squadron Master Fund LP | 31 Mar 2026 | ||
| TRAW | Traws Pharma, Inc. | Common Stock, par value $.01 per share | 6.4% | $936,437 | -$369,342 | 511,714 | -28% | Squadron Master Fund LP | 31 Mar 2026 |
| LPCN | Lipocine Inc. | Common Stock, par value $0.0001 per share | 6.2% | $940,500 | -$167,200 | 450,000 | -15% | Squadron Master Fund LP | 31 Mar 2026 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Common Stock,$0.001 par value per share | 5.1% | $9,376,095 | 3,676,900 | Squadron Master Fund LP | 24 Feb 2026 | ||
| CCCC | C4 Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 5% | $16,206,000 | 5,550,000 | Squadron Master Fund LP | 12 May 2026 | ||
| PALI | PALISADE BIO, INC. | Common Stock, par value $0.01 per share | 3% | $8,640,000 | -$7,200,000 | 4,500,000 | -45% | Squadron Master Fund LP | 31 Dec 2025 |
| SPRB | SPRUCE BIOSCIENCES, INC. | Common Stock, par value $0.0001 per share | 0.9% | $787,022 | -$3,728,678 | 12,200 | -83% | Squadron Master Fund LP | 31 Mar 2026 |
Schedules 13D/G Reported by Squadron Capital Management LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.